Article (Scientific journals)
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.
Wlodarczyk, Z.; Squifflet, Jean-Paul; Ostrowski, M. et al.
2009In American Journal of Transplantation, 9 (11), p. 2505-13
Peer Reviewed verified by ORBi
 

Files


Full Text
pharmacokinetics.pdf
Publisher postprint (362.5 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Aged; Delayed-Action Preparations; Female; Follow-Up Studies; Graft Rejection/drug therapy; Humans; Immunosuppressive Agents/administration & dosage/adverse effects/pharmacokinetics; Kidney Transplantation; Male; Middle Aged; Tacrolimus/administration & dosage/adverse effects/pharmacokinetics; Young Adult
Abstract :
[en] Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). A once-daily prolonged-release formulation (Tacrolimus QD) has been developed that may improve adherence and impart long-lasting graft protection. This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or Tacrolimus BID. A 6-week, open-label, randomized comparative study was conducted in centers in Europe and Australia. Eligible patients received Tacrolimus QD or Tacrolimus BID. PK profiles were obtained following the first tacrolimus dose (day 1), and twice under steady-state conditions. As secondary objectives, efficacy and safety parameters were also evaluated. Sixty-six patients completed all PK profiles (34 Tacrolimus QD, 32 Tacrolimus BID). Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4. There was a good correlation and a similar relationship between AUC(0-24) and C(min) for both formulations. Efficacy and safety data were also comparable over the 6-week period. Tacrolimus QD can be administered once daily in the morning on the basis of the same systemic exposure and therapeutic drug monitoring concept as Tacrolimus BID.
Disciplines :
Surgery
Author, co-author :
Wlodarczyk, Z.
Squifflet, Jean-Paul ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Ostrowski, M.
Rigotti, P.
Stefoni, S.
Citterio, F.
Vanrenterghem, Y.
Kramer, B. K.
Abramowicz, Daniel
Oppenheimer, F.
Pietruck, F.
Russ, G.
Karpf, C.
Undre, N.
More authors (4 more) Less
Language :
English
Title :
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.
Publication date :
2009
Journal title :
American Journal of Transplantation
ISSN :
1600-6135
eISSN :
1600-6143
Publisher :
Blackwell Publishing
Volume :
9
Issue :
11
Pages :
2505-13
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 26 January 2010

Statistics


Number of views
80 (9 by ULiège)
Number of downloads
4 (4 by ULiège)

Scopus citations®
 
109
Scopus citations®
without self-citations
94
OpenCitations
 
105

Bibliography


Similar publications



Contact ORBi